Form D · Biotechnology
Flavocure Biotech, Inc.
Baltimore, MD · CIK 0001960342
Offering snapshot reported Feb 21, 2025 · SEC filing
- Reported sold
- $215K Offering amount: $2M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Feb 5, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 21, 2025 | Initial | $215,000 | No comparison | 3 | SEC filing |
| Jan 4, 2023 | Initial | $1,125,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-538836
Source: Form D, filed Feb 21, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Brooks | Executive |
| Eric Chapman | Promoter |
| Anthony Deasey | Promoter |
| Justin Grant | Director |
| Thomas Lang | Executive |
| Douglas Liu | Executive |
| Henry Lowe | Director, Executive |
| Saurabh Sewak | Promoter |
| Swen Simms | Promoter |
| Ngeh Toyang | Director, Executive |
| Theresia Toyeng | Promoter |
| David Traylor | Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
701 E Pratt St Ste 2033
Baltimore, MD, 21202
Baltimore, MD, 21202